13058_2021_1390_MOESM1_ESM.docx (280.08 kB)
Download file

Additional file 1 of RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

Download (280.08 kB)
journal contribution
posted on 2021-03-31, 03:43 authored by Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha, Andrew R. Green, Patricia G. Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, Aleix Prat, Teresa Puig, Eva Gonzalez-Suarez
Additional file 1: Figure S1. TMA H-scores and controls. A. RANK and RANKL H-scores in HER2-positive breast cancer samples, treatment-naïve (left panels) or anti-HER2-resistant (right panels). In treatment-naïve TMAs, each number represents a “core” from a single patient. In anti-HER2-resistant TMAs, scored independent tumor cores are numbered for each patient (after the symbol #). B. Representative pictures of human breast tumors from patient-derived xenografts used as positive and negative controls for RANK and RANKL IHC.


Fundació la Marató de TV3 (ES) Ministerio de Ciencia, Innovación y Universidades Susan G. Komen Instituto de Salud Carlos III Breast Cancer Research Foundation (US) European Research Council Fundación Científica Asociación Española Contra el Cáncer